Epocrates Launches Application for iPad and iPad mini
Sleek Design and Intuitive User Experience Receives Rave Reviews from Clinicians
SAN MATEO, Calif., December 6, 2012 – Epocrates, Inc., developers of the first and most popular medical application for the Apple iPhone®, today announced the release of a native app for the iPad® and iPad® mini tablets. Designed explicitly for these tablet devices, Epocrates for iPad provides an elegant and efficient user experience with even more streamlined access to the clinical information that more than one million clinicians routinely rely on during and between patient encounters.
"We deliberately built the Epocrates iPad app based on the needs and input of our clinician network to create sleek, practical and intuitive workflows," said Andy Hurd, president, chief executive officer and interim chief financial officer of Epocrates.
Healthcare professionals are enthusiastic about the new app, providing initial feedback, such as:
- "I primarily use Epocrates with patients for a quick reference on a daily basis. The new iPad app is so fast, and conveniently displays both adult and pediatric dosing side by side," said Dr. Deborah Archer, Fort Collins, Colo.
- "Epocrates has definitely impacted patient care and quality; it is an essential tool. With the iPad app, all of the information is bigger and more prominent, and I can swivel the tablet around and share it with my patients," said Dr. Nancy Lawless, Rockville, Md.
- "The new Epocrates app has a slicker design; it's nice having all information displayed in one place," said Dr. Franklin Schneider, Providence, R.I.
With a form factor larger than a smartphone and lighter than a laptop, tablets have established a role in today's digital healthcare setting. Seventy five percent of physicians are predicted to own a tablet by April 2013 with preference for iPad devices. The native Epocrates app takes advantage of the larger screen real estate, providing greater exposure to critical clinical information, enhanced pill identification displays and more convenient search tools. It leverages the devices' swiping capabilities for rapid navigation, and features tabbed screens for easy toggling between multiple drug monographs, calculators and other valuable content.
Hurd added, "we see significant opportunities with the release of this native iPad app, and for future iterations to build on clinical capabilities, rich patient engagement and innovative solutions for our partners."
Epocrates for iPad is now available in the Apple iTunes Store. For more information and a demonstration video, please visit www.epocrates.com/mobile/ipad. The company also announced that an optimized version for iPhone 5 will be available in the next app release.
About Epocrates, Inc.
Epocrates, Inc. (Nasdaq: EPOC) is recognized for developing the #1 medical application among U.S. physicians for clinical content, practice tools and health industry engagement at the point of care. Epocrates has established a loyal network of more than one million healthcare professionals, including 50 percent of U.S. physicians, who routinely use its intuitive solutions to help streamline workflow and improve patient care. The company also facilitates the delivery of valuable content and tools between partnering organizations and its members. For more information, please visit www.epocrates.com/company.
Epocrates is a trademark of Epocrates, Inc., registered in the U.S. and other countries.
All statements contained in this press release, other than statements of historical fact, are forward-looking statements intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. The forward-looking statements include uncertainties and risks including, among others: the inability to retain and expand the Epocrates physician network at the rate expected; unexpected delays in delivering new products; lack of market acceptance of new products; the inability to maintain product quality and brand credibility; the inability to keep up with the technological advances within the marketplace and by competitors; the inability to realize estimates and guidance made by management with respect to Epocrates' financial results; and other factors, including general economic conditions and regulatory developments not within Epocrates' control. The factors discussed herein and expressed from time to time in Epocrates' filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release, and except as required by law, Epocrates undertakes no obligation to publicly update its forward-looking statements to reflect subsequent events or circumstances. You should review the Epocrates' filings, especially the risk factors contained in its most recent filings with the Securities and Exchange Commission on Form 10-K and Form 10-Q.